Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-blocker use in decompensated heart failure.

Rami Alharethi1, Ray E Hershberger

  • 1Division of Cardiology, UHN-62, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.

Current Heart Failure Reports
|August 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Common <i>CD36</i> Variant and the Genetic Landscape of Dilated Cardiomyopathy in Individuals of African Ancestry.

medRxiv : the preprint server for health sciences·2026
Same author

Integrative Clinical-Molecular Modeling Identifies <i>LRRN4CL</i> as a Determinant of Structural and Functional Myocardial Improvement.

bioRxiv : the preprint server for biology·2026
Same author

Care Models for the Genetic Evaluation of Dilated Cardiomyopathy at Sites of the DCM Consortium.

medRxiv : the preprint server for health sciences·2026
Same author

Evaluation of Women With Peripartum or Dilated Cardiomyopathy and Their First-Degree Relatives: The DCM Precision Medicine Study.

Circulation. Genomic and precision medicine·2026
Same author

The Role of Sphingolipids in Myocardial Recovery Mediated by Mechanical Unloading and Circulatory Support.

JACC. Basic to translational science·2025
Same author

Association of Kidney Function With Myocardial Recovery and Adverse Events Following Left Ventricular Assist Device Circulatory Support.

Journal of the American Heart Association·2025
Same journal

From Cardioprotection to Trial Design: Rethinking Cardiac Safety in Oncology.

Current heart failure reports·2026
Same journal

Acute and Chronic Myocarditis in Men and Women.

Current heart failure reports·2026
Same journal

Smart Technology, Fragile Hearts: Navigating AI's Challenges and Limitations in Heart Failure Management.

Current heart failure reports·2026
Same journal

Palliative Care in Advanced Heart Failure.

Current heart failure reports·2026
Same journal

The Evolving Utility of Artificial Intelligence-Based Tools for the Detection of Heart Failure and Cardiomyopathies: From Potential to Implementation.

Current heart failure reports·2026
Same journal

Emerging Artificial Intelligence Tools for the Screening of Structural and Valvular Heart Disease.

Current heart failure reports·2026
See all related articles

Managing acute decompensated heart failure in patients on beta-blockers is complex. This review addresses beta-blocker dosage and inotropic therapy integration for heart failure patients.

Area of Science:

  • Cardiology
  • Internal Medicine

Background:

  • Acute decompensated heart failure (ADHF) leads to over 1 million annual hospitalizations.
  • Many ADHF patients are already on long-term beta-blocker therapy.
  • Optimal management of these patients remains a clinical challenge.

Purpose of the Study:

  • To discuss management strategies for ADHF patients on beta-blockers.
  • To review literature on beta-blocker dosage adjustments in ADHF.
  • To explore the integration of inotropic and beta-blocker therapies.

Main Methods:

  • Literature review of existing studies on ADHF management.
  • Discussion of clinical approaches to complex patient cases.
  • Analysis of challenges in beta-blocker therapy and inotropic support.

Related Experiment Videos

Main Results:

  • Limited systematic evaluation exists for these specific clinical scenarios.
  • Clinical approaches vary due to lack of definitive guidelines.
  • Integration of therapies requires careful consideration of patient-specific factors.

Conclusions:

  • Further research is needed to establish clear guidelines for ADHF management in beta-blocker patients.
  • Clinical judgment is crucial in adjusting beta-blocker doses and combining therapies.
  • Individualized treatment plans are essential for optimizing outcomes in ADHF.